YONKERS, N.Y.--(BUSINESS WIRE)--Advanced Viral Research Corp. (OTCBB: ADVR), a research based biopharmaceutical company dedicated to anti-cancer drug discovery and development, today announced the acquisition of certain assets originally owned by Cetek Corporation, a Boston based biopharmaceutical company. These assets were recently transferred to the founding scientists at Cetek. The agreement includes rights to two new anti-cancer compounds as well as a proprietary high-throughput affinity based drug screening technology referred to as AFP. In addition, ADVR will receive rights to a diverse microbial culture library for screening potential drug candidates. Under terms of the agreement, employment contracts have been signed with three former Cetek senior scientists. The three scientists joining ADVR are Dr. Vincent Gullo as Chief Scientific Officer, Dr. Dallas Hughes as Vice President of Research, and Dr. Yuriy Dunayevskiy as Research Fellow.
